MX2022013901A - Composicion para la prevencion y el tratamiento de estados carenciales de folato y/o de vitamina b12, en particular la hiperhomocisteinemia. - Google Patents
Composicion para la prevencion y el tratamiento de estados carenciales de folato y/o de vitamina b12, en particular la hiperhomocisteinemia.Info
- Publication number
- MX2022013901A MX2022013901A MX2022013901A MX2022013901A MX2022013901A MX 2022013901 A MX2022013901 A MX 2022013901A MX 2022013901 A MX2022013901 A MX 2022013901A MX 2022013901 A MX2022013901 A MX 2022013901A MX 2022013901 A MX2022013901 A MX 2022013901A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- vitamin
- hyperhomocysteinemia
- folate
- prevention
- Prior art date
Links
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 235000019152 folic acid Nutrition 0.000 title abstract 3
- 239000011724 folic acid Substances 0.000 title abstract 3
- 208000033892 Hyperhomocysteinemia Diseases 0.000 title abstract 2
- 229940014144 folate Drugs 0.000 title abstract 2
- 230000003225 hyperhomocysteinemia Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 206010016880 Folate deficiency Diseases 0.000 title 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 title 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 abstract 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 239000011715 vitamin B12 Substances 0.000 abstract 2
- 235000019163 vitamin B12 Nutrition 0.000 abstract 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract 1
- 230000003113 alkalizing effect Effects 0.000 abstract 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000292 calcium oxide Substances 0.000 abstract 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960000304 folic acid Drugs 0.000 abstract 1
- 239000000395 magnesium oxide Substances 0.000 abstract 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 abstract 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
- 239000011787 zinc oxide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Una composición para uso oral que comprende ácido fólico o derivados y precursores del mismo, un agente alcalinizante seleccionado del grupo que consiste en Óxido de Magnesio, Óxido de Calcio, Óxido de Zinc y mezclas de los mismos, y opcionalmente vitamina B12 o derivados y precursores de la misma. La composición está destinada al tratamiento y/o prevención de los estados de enfermedad causados por la deficiencia de folato y/o vitamina B12, en particular la hiperhomocisteinemia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000010228A IT202000010228A1 (it) | 2020-05-07 | 2020-05-07 | Composizione per la prevenzione e il trattamento di condizioni da carenza di folati e/o vitamina b12, particolarmente iperomocisteinemia |
| PCT/IB2021/053853 WO2021224854A1 (en) | 2020-05-07 | 2021-05-06 | Composition for the prevention and treatment of folate and/or vitamin b12 deficiency conditions, particularly hyperhomocysteinemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013901A true MX2022013901A (es) | 2023-02-09 |
Family
ID=71895084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013901A MX2022013901A (es) | 2020-05-07 | 2021-05-06 | Composicion para la prevencion y el tratamiento de estados carenciales de folato y/o de vitamina b12, en particular la hiperhomocisteinemia. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230172966A1 (es) |
| EP (1) | EP4146167A1 (es) |
| CA (1) | CA3182363A1 (es) |
| IT (1) | IT202000010228A1 (es) |
| MX (1) | MX2022013901A (es) |
| PH (1) | PH12022553005A1 (es) |
| WO (1) | WO2021224854A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119143617B (zh) * | 2024-11-19 | 2025-03-04 | 山东祥维斯医药科技有限公司 | 一种含磷酸甜菜碱的药物组合物、制备方法及在制备治疗甲基丙二酸血症合并同型半胱氨酸血症的药物中的应用 |
| CN120859963B (zh) * | 2025-09-26 | 2025-12-09 | 湖南状元制药有限公司 | 甲钴胺缓释微片及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10022510A1 (de) * | 2000-05-10 | 2001-11-15 | Basf Ag | Zusammensetzungen enthaltend Folsäure und reduziertes Folat |
| US20080063730A9 (en) * | 2004-07-29 | 2008-03-13 | Giordano John A | Methods for prophylactic and therapeutic nutritional supplementation |
| US20060217385A1 (en) * | 2005-03-10 | 2006-09-28 | Edwards John B | Nutritional preparations |
| US20060251722A1 (en) * | 2005-05-03 | 2006-11-09 | Novavax, Inc. | Multi-component vitamin and mineral supplement for the optimal absorption of components |
| CN101282735A (zh) * | 2005-10-11 | 2008-10-08 | 拜耳消费者保健股份公司 | 掩蔽金属味道的铁盐和铜盐混合物 |
| US8183227B1 (en) * | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
-
2020
- 2020-05-07 IT IT102020000010228A patent/IT202000010228A1/it unknown
-
2021
- 2021-05-06 EP EP21729934.6A patent/EP4146167A1/en active Pending
- 2021-05-06 CA CA3182363A patent/CA3182363A1/en active Pending
- 2021-05-06 WO PCT/IB2021/053853 patent/WO2021224854A1/en not_active Ceased
- 2021-05-06 PH PH1/2022/553005A patent/PH12022553005A1/en unknown
- 2021-05-06 US US17/997,833 patent/US20230172966A1/en active Pending
- 2021-05-06 MX MX2022013901A patent/MX2022013901A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022553005A1 (en) | 2024-05-20 |
| IT202000010228A1 (it) | 2021-11-07 |
| EP4146167A1 (en) | 2023-03-15 |
| US20230172966A1 (en) | 2023-06-08 |
| WO2021224854A1 (en) | 2021-11-11 |
| CA3182363A1 (en) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018004175B8 (pt) | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto | |
| CY1125329T1 (el) | Αντιιικες ενωσεις πυραζολο- και τριαζολο-πυριμιδινης εναντι toy rsv | |
| MY208632A (en) | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors | |
| PH12018502307A1 (en) | Aromatic sulfonamide derivatives | |
| MX2019002265A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| MX389244B (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer | |
| ECSP066990A (es) | Formulaciones con liberación controlada de principio activo que contienen vardenafilo | |
| BR112018014545A2 (pt) | probióticos para uso como agentes anti-inflamatórios na cavidade oral | |
| FIC20190031I1 (fi) | Rifamysiini SV | |
| MX2015010139A (es) | Composicion antiseptica oral para tratamiento de mucositis oral. | |
| MX2022013901A (es) | Composicion para la prevencion y el tratamiento de estados carenciales de folato y/o de vitamina b12, en particular la hiperhomocisteinemia. | |
| MX388378B (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
| NZ598171A (en) | Methods and compositions for treating thyroid-related medical conditions with reduced folates | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| BR112019003136A2 (pt) | forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo | |
| EP4272832A3 (en) | Antimicrobial compounds, compositions, and uses thereof | |
| MX2019007555A (es) | Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional. | |
| CL2023001016A1 (es) | Biofactores para el tratamiento y la profilaxis de demencia | |
| PH12020550222A1 (en) | Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections | |
| PH12020550673A1 (en) | Pyrazolopyrimidines having activity against the respiratory syncytial virus (rsv) | |
| BR112023025789A2 (pt) | Nitroxolina para uso no tratamento de neurofibroma cutâneo | |
| BR112018010497A8 (pt) | combinação sinérgica de ácido pirrolidona-carboxílico e/ou seus sais e de ácido hialurônico e/ou seus sais para utilização no tratamento e/ou prevenção de secura e irritação da mucosa e suas formulações farmaceuticas relacionadas | |
| MX2022006179A (es) | Derivados macrociclicos de indol como inhibidores de mcl-1. | |
| GEP20227372B (en) | Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof | |
| MX2022006180A (es) | Derivados macrociclicos de sulfonilo como inhibidores de mcl-1. |